Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva
| Autor: | Onno W. Akkerman, Mireille A. Wessels, Samiksha Ghimire, Daan J Touw, Jan-Willem C. Alffenaar, Erwin M Jongedijk, Simone H J van den Elsen, Mathieu S. Bolhuis, Tjip S. van der Werf |
|---|---|
| Přispěvatelé: | Microbes in Health and Disease (MHD), Pharmaceutical Analysis, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Groningen Research Institute for Asthma and COPD (GRIAC), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Medicinal Chemistry and Bioanalysis (MCB) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Tuberculosis Antitubercular Agents Drug resistance Discount points Nothing medicine Isoniazid Humans Intensive care medicine Saliva medicine.diagnostic_test business.industry Conflict of interest Mycobacterium tuberculosis medicine.disease Pharmaceutical Preparations Therapeutic drug monitoring Drug Monitoring Rifampin business Rifampicin medicine.drug |
| Zdroj: | European Respiratory Journal, 56(4):2000803. EUROPEAN RESPIRATORY SOC JOURNALS LTD |
| ISSN: | 0903-1936 |
| Popis: | The persisting worldwide burden of tuberculosis (TB) is worrisome. In 2018, an estimated 10 million individuals developed TB and 1.45 million deceased [1]. The increase in drug resistance is an important point of concern. Resistance can be acquired by inappropriate drug management, non-compliance, and insufficient drug exposure [2, 3]. The last is frequently described for the first-line TB drugs rifampicin and isoniazid due to large inter-individual pharmacokinetic variability [3]. Therapeutic drug monitoring (TDM) can be used to verify drug exposure and adjust individual drug dosages if needed [4]. The efficacy of rifampicin and isoniazid is associated with the ratio of the steady-state area under the concentration-time curve from 0 to 24 h to minimal inhibitory concentration (AUC0–24/MIC) with a target value of >271 for rifampicin and >567 for isoniazid [5, 6]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. van den Elsen has nothing to disclose. Conflict of interest: Dr. Akkerman has nothing to disclose. Conflict of interest: Dr. Wessels has nothing to disclose. Conflict of interest: Dr. Jongedijk has nothing to disclose. Conflict of interest: Dr. Ghimire has nothing to disclose. Conflict of interest: Dr. van der Werf has nothing to disclose. Conflict of interest: Dr. Bolhuis has nothing to disclose. Conflict of interest: Dr. Touw has nothing to disclose. Conflict of interest: Dr. Alffenaar has nothing to disclose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|